New filings and stem cell deal hold out promise for MS
This article was originally published in Scrip
The recent US and EU filings for Novartis' fingolimod and the announcement of a UK collaboration on stem cell research are welcome developments for multiple sclerosis patients and doctors awaiting potential new treatments for this intractable and distressing disease.
You may also be interested in...
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.